Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | APC |
Variant | G1120E |
Impact List | missense |
Protein Effect | no effect - predicted |
Gene Variant Descriptions | APC G1120E lies within the beta-catenin binding domain of the Apc protein (PMID: 14672538). G1120E inhibits beta-catenin mediated transcription at a level similar to wild-type Apc in a yeast assay (PMID: 14633595), and therefore, is predicted to have no effect on Apc protein function. |
Associated Drug Resistance | |
Category Variants Paths |
APC mutant APC G1120E |
Transcript | NM_000038.6 |
gDNA | chr5:g.112838953G>A |
cDNA | c.3359G>A |
Protein | p.G1120E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000038.5 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_000038 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001354895.2 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001407454.1 | chr5:g.112839202G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001407450.1 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001407455.1 | chr5:g.112839202G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001407457.1 | chr5:g.112839202G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001354895.1 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001127510.2 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001407456.1 | chr5:g.112839202G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001127510 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_001127510.3 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
NM_000038.6 | chr5:g.112838953G>A | c.3359G>A | p.G1120E | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|